$0.759
+0.042 (+5.50%)At close
BRNS Comparative Benchmarking
In the context of the broader market, BRNS competes directly with industry leaders such as NNVC and ATNM. With a market capitalization of $29.39M, it holds a significant position in the sector. When comparing efficiency, BRNS's gross margin of N/A stands against NNVC's N/A and ATNM's 100.00%. Such benchmarking helps identify whether Barinthus Biotherapeutics PLC is trading at a premium or discount relative to its financial performance.
Barinthus Biotherapeutics PLC Financial Performance
The company has reported substantial net losses, including -$10.58 million in Q2 2026 and a negative EPS of -0.26. However, it has a strong gross margin of 100% in Q3 2024, but this has not been sustained in recent quarters.
Financials
This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.